Haloperidol Half-Life
The elimination half-life of haloperidol is approximately 18 hours after both oral and intramuscular administration, with a range of 15-25 hours depending on the patient population and route.
Pharmacokinetic Parameters by Route
Oral Administration
After oral dosing, haloperidol demonstrates:
- Elimination half-life: 17.5-18.1 hours 1, 2, 3
- Bioavailability: approximately 60-65% due to first-pass hepatic metabolism 1, 2, 3
- Lag time before absorption: 0.8-1.3 hours 1, 3
- Absorption half-life: 0.4-1.9 hours 1, 3
- Peak plasma levels occur within 2-6 hours after oral dosing
Intramuscular Administration
After IM injection of standard haloperidol formulation:
- Elimination half-life: 15.1 hours 2
- The elimination kinetics are similar to oral administration once absorbed
- Faster onset compared to oral route due to bypassing first-pass metabolism
Intramuscular Decanoate (Long-Acting)
The decanoate formulation has distinctly different pharmacokinetics:
- Half-life: approximately 3 weeks (21 days) 4
- Peak plasma levels occur within 3-7 days after injection
- Steady-state is reached within 3 months with monthly dosing 4
Clinical Implications
The relatively long 18-hour half-life means haloperidol can be dosed once or twice daily for maintenance therapy, and steady-state concentrations are typically achieved after 4-5 days of regular dosing (approximately 4-5 half-lives).
Important Pharmacokinetic Characteristics
- Large volume of distribution: 17.8 L/kg 3, explaining the long half-life despite hepatic metabolism
- Blood clearance: 550 ml/min 1
- Hepatic extraction ratio: intermediate (0.37) 1
- Extensive tissue distribution, with concentrations in fatty tissue 10-20 times higher than serum and liver tissue 325-900 times higher than serum 5
Factors Affecting Half-Life
The half-life can be influenced by:
- Hepatic function: Patients with severe hepatic dysfunction may have prolonged elimination
- Drug interactions: CYP3A4 inducers (rifampin, carbamazepine, phenytoin) can decrease haloperidol levels by up to 70%, while CYP3A4 and CYP2D6 inhibitors can increase levels 6, 7
- Individual patient variability: The standard deviation in studies shows considerable inter-patient variation (±6-9 hours) 1, 2, 3
Clinical Monitoring Considerations
Given the 18-hour half-life, when discontinuing haloperidol or adjusting doses:
- Allow 4-5 days for new steady-state to be reached
- Extrapyramidal symptoms may persist after discontinuation due to the difference in excretion rates between haloperidol and anticholinergic antiparkinson medications 7
- When switching from enzyme inducers, haloperidol concentrations may gradually increase over several days, potentially requiring dose reduction 6